ROLE OF COMPLEMENT ACTIVATION IN HYPERSENSITIVITY REACTIONS TO DOXIL AND HYNIC PEG LIPOSOMES: EXPERIMENTAL AND CLINICAL STUDIES
暂无分享,去创建一个
F M Muggia | J Szebeni | A. Chanan-Khan | G. Storm | C. Alving | J. Szebeni | R. Cohen | P. Laverman | F. Muggia | R. Bünger | C R Alving | S Savay | Y Barenholz | L. Liebes | J. Metselaar | L. Baranyi | S. Sávay | J. Milosevits | R. Bunger | P Laverman | G Storm | A Chanan-Khan | L Liebes | L Baranyi | J Milosevits | R Bunger | J M Metselaar | R Cohen | Y. Barenholz
[1] H. Lutz,et al. The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil®) , 2000 .
[2] Y. Barenholz,et al. Clinical studies of liposome-encapsulated doxorubicin. , 1994, Acta oncologica.
[3] A. Gabizon,et al. Initial Clinical Evaluation of Pegylated-Liposomal Doxorubicin in Solid Tumors , 1998 .
[4] W. Oyen,et al. Tc-99m-PEG-Liposomes for the Evaluation of Colitis in Crohn's Disease , 2000, Journal of drug targeting.
[5] A. Gabizon,et al. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] S. de Marie. Liposomal and lipid-based formulations of amphotericin B. , 1996, Leukemia.
[7] A. Gabizon. Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.
[8] J Szebeni,et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. , 1999, Circulation.
[9] A. Giatromanolaki,et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] DifcoTM HycheckTM,et al. The package insert. , 1969, JAMA.
[11] F. Muggia,et al. Liposomal encapsulated anthracyclines: new therapeutic horizons , 2001, Current oncology reports.
[12] J. Codina,et al. Sch-28080 depletes intracellular ATP selectively in mIMCD-3 cells. , 2000, American journal of physiology. Cell physiology.
[13] Y. Barenholz,et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.
[14] M. Bodó,et al. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. , 2000, American journal of physiology. Heart and circulatory physiology.
[15] J. Szebeni,et al. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. , 2001, Critical reviews in therapeutic drug carrier systems.
[16] F M Muggia,et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.